BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

382 related articles for article (PubMed ID: 15284715)

  • 21. Ashkenazi founder BRCA1/BRCA2 mutations in Slovak hereditary breast and/or ovarian cancer families.
    Cierniková S; Tomka M; Kovác M; Stevurková V; Zajac V
    Neoplasma; 2006; 53(2):97-102. PubMed ID: 16575464
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
    Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
    Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Psychosocial issues following a positive result of genetic testing for BRCA1 and BRCA2 mutations: findings from a focus group and a needs-assessment survey.
    Di Prospero LS; Seminsky M; Honeyford J; Doan B; Franssen E; Meschino W; Chart P; Warner E
    CMAJ; 2001 Apr; 164(7):1005-9. PubMed ID: 11314429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinicians' attitudes toward general screening of the Ashkenazi-Jewish population for prevalent founder BRCA1/2 and LRRK2 mutations.
    Shkedi-Rafid S; Ofer-Bialer G; Meiner V; Calderon-Margalit R
    Public Health Genomics; 2013; 16(4):174-83. PubMed ID: 23816973
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of BRCA1 and BRCA2 mutations in a large United States sample.
    Chen S; Iversen ES; Friebel T; Finkelstein D; Weber BL; Eisen A; Peterson LE; Schildkraut JM; Isaacs C; Peshkin BN; Corio C; Leondaridis L; Tomlinson G; Dutson D; Kerber R; Amos CI; Strong LC; Berry DA; Euhus DM; Parmigiani G
    J Clin Oncol; 2006 Feb; 24(6):863-71. PubMed ID: 16484695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patient satisfaction and cancer-related distress among unselected Jewish women undergoing genetic testing for BRCA1 and BRCA2.
    Metcalfe KA; Poll A; Llacuachaqui M; Nanda S; Tulman A; Mian N; Sun P; Narod SA
    Clin Genet; 2010 Nov; 78(5):411-7. PubMed ID: 20653694
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations.
    Casey MJ; Bewtra C
    Fam Cancer; 2004; 3(3-4):265-81. PubMed ID: 15516851
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRCA1 mutations in women attending clinics that evaluate the risk of breast cancer.
    Couch FJ; DeShano ML; Blackwood MA; Calzone K; Stopfer J; Campeau L; Ganguly A; Rebbeck T; Weber BL
    N Engl J Med; 1997 May; 336(20):1409-15. PubMed ID: 9145677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.
    Green MJ; Peterson SK; Baker MW; Harper GR; Friedman LC; Rubinstein WS; Mauger DT
    JAMA; 2004 Jul; 292(4):442-52. PubMed ID: 15280342
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Benefit finding in response to BRCA1/2 testing.
    Low CA; Bower JE; Kwan L; Seldon J
    Ann Behav Med; 2008 Feb; 35(1):61-9. PubMed ID: 18347905
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key messages for communicating information about BRCA1 and BRCA2 to women with breast or ovarian cancer: Consensus across health professionals and service users.
    Jacobs C; Pichert G; Harris J; Tucker K; Michie S
    Psychooncology; 2017 Nov; 26(11):1818-1824. PubMed ID: 28101941
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Incidence of BRCA1 and BRCA2 non-founder mutations in patients of Ashkenazi Jewish ancestry.
    Rosenthal E; Moyes K; Arnell C; Evans B; Wenstrup RJ
    Breast Cancer Res Treat; 2015 Jan; 149(1):223-7. PubMed ID: 25476495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Germline BRCA1-2 mutations in non-Ashkenazi families with double primary breast and ovarian cancer.
    Schorge JO; Mahoney NM; Miller DS; Coleman RL; Muller CY; Euhus DM; Tomlinson GE
    Gynecol Oncol; 2001 Nov; 83(2):383-7. PubMed ID: 11606101
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience.
    Bakos AD; Hutson SP; Loud JT; Peters JA; Giusti RM; Greene MH
    Health Expect; 2008 Sep; 11(3):220-31. PubMed ID: 18816319
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Familial clustering of site-specific cancer risks associated with BRCA1 and BRCA2 mutations in the Ashkenazi Jewish population.
    Simchoni S; Friedman E; Kaufman B; Gershoni-Baruch R; Orr-Urtreger A; Kedar-Barnes I; Shiri-Sverdlov R; Dagan E; Tsabari S; Shohat M; Catane R; King MC; Lahad A; Levy-Lahad E
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3770-4. PubMed ID: 16537453
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA1 gene mutations may explain more than 80% of excess number of ovarian cancer cases after breast cancer - a population based study from the Western Sweden Health Care region.
    Einbeigi Z; Enerbäck C; Wallgren A; Nordling M; Karlsson P
    Acta Oncol; 2010 Apr; 49(3):361-7. PubMed ID: 20151938
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of germline genetic mutations in patients with pancreatic cancer.
    Salo-Mullen EE; O'Reilly EM; Kelsen DP; Ashraf AM; Lowery MA; Yu KH; Reidy DL; Epstein AS; Lincoln A; Saldia A; Jacobs LM; Rau-Murthy R; Zhang L; Kurtz RC; Saltz L; Offit K; Robson ME; Stadler ZK
    Cancer; 2015 Dec; 121(24):4382-8. PubMed ID: 26440929
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Perceptions of Ashkenazi Jewish breast cancer patients on genetic testing for mutations in BRCA1 and BRCA2.
    Phillips KA; Warner E; Meschino WS; Hunter J; Abdolell M; Glendon G; Andrulis IL; Goodwin PJ
    Clin Genet; 2000 May; 57(5):376-83. PubMed ID: 10852372
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.